R&D will continue to dive Biocon run: Gaurang Shah
R&D could put pressure on the cash flows at least in the short to medium term but over a longer period of time we do remain positive on Biocon.
By 
| Updated:
| Updated: In a chat with ET Now, Gaurang Shah, VP, Geojit BNP Paribas Financial Services shares his views on Biocon.
ET NOW: What is your view on Biocon?
Gaurang Shah: Yes, we do have a Malaysian facility up and running in the next year or two should augur well for Biocon. There are news flows of further investment in R&D and if you just look back about two or three years back the invested about 153,000 odd crore in the R&D and the result of that you have seen in the recent times.
The recent launches that they have done have got them a good price. So, my understanding is that if they continue with this kind of run rate of course that investment in R&D could put pressure on the cash flows at least in the short to medium term but over a longer period of time we do remain positive on Biocon.
ET NOW: What is your view on Biocon?
Gaurang Shah: Yes, we do have a Malaysian facility up and running in the next year or two should augur well for Biocon. There are news flows of further investment in R&D and if you just look back about two or three years back the invested about 153,000 odd crore in the R&D and the result of that you have seen in the recent times.
The recent launches that they have done have got them a good price. So, my understanding is that if they continue with this kind of run rate of course that investment in R&D could put pressure on the cash flows at least in the short to medium term but over a longer period of time we do remain positive on Biocon.
Too busy to trade in stocks? Invest in Mutual Funds with ET Money!
Bookmark or read stories offline -
Download ET Markets APP
Download ET Markets APP
ADVERTISEMENT
